Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what to expect. Repligen beat analysts’ revenue expectations last ...
Repligen Corporation RGEN reported fourth-quarter 2025 adjusted earnings per share of 49 cents, which came ahead of the Zacks Consensus Estimate and the year-ago adjusted earnings of 44 cents per ...
Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here. The fund rose 13.10% ...
Repligen Corporation (NASDAQ:RGEN) reported in-line earnings for its second quarter on Tuesday. The company posted second-quarter sales of $154.1 million, almost in line with the consensus estimate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results